By admin | Published:
December 21, 2005
December 21, 2005
Sandra Horning
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Click here for all the interviews from ASH 2005
By admin | Published:
December 21, 2005
December 21, 2005
Vincent Rajkumar
Vincent Rajkumar, Divison of Hematology, Mayo Clinic
At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkumar discussed new agents such as lenolidamide and thalidomide. Audio Medica asked him how he makes decisions about how to treat multiple myeloma.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Click here for all the interviews from ASH 2005
Posted in ASH 2005 | Tagged ash, myeloma |
By admin | Published:
December 21, 2005
December 21, 2005
Owen O’Connor
Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Click here for all the interviews from ASH 2005
Posted in ASH 2005 | Tagged ash, drug, lymphoma |